Yevhen Hotko

3.2k total citations · 1 hit paper
26 papers, 1.4k citations indexed

About

Yevhen Hotko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Yevhen Hotko has authored 26 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Yevhen Hotko's work include Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (4 papers). Yevhen Hotko is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Lung Cancer Treatments and Mutations (11 papers) and Lung Cancer Research Studies (4 papers). Yevhen Hotko collaborates with scholars based in Ukraine, United States and Australia. Yevhen Hotko's co-authors include Marc Peeters, Andrés Cervantes, Thierry André, Timothy Price, Michel Ducreux, Florian Lordick, G. Wilson, Cornelis J.A. Punt, Tudor–Eliade Ciuleanu and Laslo Roman and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Yevhen Hotko

24 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yevhen Hotko Ukraine	13	1.2k	609	315	279	208	26	1.4k
Allert H. Vos Netherlands	8	1.3k 1.1×	542 0.9×	325 1.0×	314 1.1×	186 0.9×	11	1.6k
S. Heeger Germany	14	895 0.7×	402 0.7×	242 0.8×	221 0.8×	188 0.9×	32	1.2k
M. Elisa Vink-Börger Netherlands	9	1.3k 1.1×	535 0.9×	487 1.5×	354 1.3×	230 1.1×	9	1.6k
Andrew Strickland Australia	12	891 0.7×	436 0.7×	278 0.9×	210 0.8×	208 1.0×	31	1.1k
Jean‐Luc Canon Belgium	11	1.6k 1.3×	691 1.1×	389 1.2×	406 1.5×	293 1.4×	12	1.8k
Annette Frost Germany	14	747 0.6×	493 0.8×	226 0.7×	207 0.7×	140 0.7×	29	1.4k
Martin Šmakal United States	11	2.1k 1.7×	896 1.5×	423 1.3×	385 1.4×	303 1.5×	26	2.6k
Ilona Kocáková Czechia	10	1.6k 1.3×	695 1.1×	404 1.3×	432 1.5×	355 1.7×	33	1.9k
B. Barón Belgium	17	649 0.5×	543 0.9×	275 0.9×	155 0.6×	356 1.7×	28	1.4k
Marianne Krahn Canada	3	1.3k 1.0×	526 0.9×	304 1.0×	249 0.9×	201 1.0×	6	1.8k

Countries citing papers authored by Yevhen Hotko

Since Specialization

Citations

This map shows the geographic impact of Yevhen Hotko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yevhen Hotko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yevhen Hotko more than expected).

Fields of papers citing papers by Yevhen Hotko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yevhen Hotko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yevhen Hotko. The network helps show where Yevhen Hotko may publish in the future.

Co-authorship network of co-authors of Yevhen Hotko

This figure shows the co-authorship network connecting the top 25 collaborators of Yevhen Hotko. A scholar is included among the top collaborators of Yevhen Hotko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yevhen Hotko. Yevhen Hotko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hotko, Yevhen, et al.. (2025). Changes in morphological and immunohistochemical parameters of tumors during neoadjuvant hormone therapy in postmenopausal patients with luminal type of breast cancer. Wiadomości Lekarskie. 78(4). 710–716.

Oliveira, Mafalda, Erika Hamilton, Yaroslav Kulyaba, et al.. (2023). Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.. Journal of Clinical Oncology. 41(16_suppl). 1066–1066. 11 indexed citations

Hotko, Yevhen, et al.. (2016). Peculiarities of breast cancer incidence rate in urban population and implementation of screening programs in health care system.. PubMed. 69(1 Pt 2). 61–3. 1 indexed citations

Cicėnas, Saulius, Sarayut Lucien Geater, Petar Petrov, et al.. (2016). Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 102. 30–37. 38 indexed citations

Pintér, Tamás, Zandra Klippel, Alvydas Česas, et al.. (2016). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical Colorectal Cancer. 16(2). 103–114.e3. 21 indexed citations

Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis. Annals of Oncology. 25. ii5–ii5. 2 indexed citations

Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(3_suppl). LBA387–LBA387. 35 indexed citations

Peeters, Marc, Kelly S. Oliner, Timothy Price, et al.. (2014). Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(15_suppl). 3568–3568. 33 indexed citations

Hotko, Yevhen, et al.. (2013). Receptor status of tumor as prognostic factor in patients with bilateral breast cancer.. The scientific electronic library of periodicals of the National Academy of Sciences of Ukraine (National Academy of Sciences of Ukraine). 35(4). 291–4. 3 indexed citations

10.

Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2013). Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology. 25(1). 107–116. 158 indexed citations

11.

Hotko, Yevhen. (2013). Male breast cancer: clinical presentation, diagnosis, treatment.. PubMed. 35(4). 303–10. 7 indexed citations

12.

Abella, Steve, Alvydas Česas, Adina Croitoru, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(4_suppl). LBA445–LBA445. 4 indexed citations

13.

Sobrero, Alberto F., Marc Peeters, Timothy Price, et al.. (2012). Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). 3535–3535. 4 indexed citations

14.

O’Byrne, Kenneth J., U. Gatzemeier, Igor Bondarenko, et al.. (2011). Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology. 12(8). 795–805. 9 indexed citations

15.

Campone, Mario, Igor Bondarenko, Stephen Brincat, et al.. (2011). Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology. 23(3). 610–617. 77 indexed citations

16.

Peeters, Marc, Timothy Price, Andrés Cervantes, et al.. (2010). Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 28(31). 4706–4713. 755 indexed citations breakdown →

17.

Peeters, Marc, Timothy Price, Yevhen Hotko, et al.. (2009). 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). European Journal of Cancer Supplements. 7(3). 10–10. 23 indexed citations

18.

O’Brien, Mary, Mark A. Socinski, Igor Bondarenko, et al.. (2008). Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(7). 728–734. 96 indexed citations

19.

Peeters, Marc, G. Wilson, Yevhen Hotko, et al.. (2008). Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: preliminary safety results.. Ghent University Academic Bibliography (Ghent University). 335–335. 8 indexed citations

20.

Kawecki, Andrzej, Douglas R. Adkins, Casey Cunningham, et al.. (2007). A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 25(18_suppl). 16509–16509. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact